Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Neurocrine Biosciences, Inc is a biotechnology business based in the US. Neurocrine Biosciences shares (NBIX) are listed on the NASDAQ and all prices are listed in US Dollars. Neurocrine Biosciences employs 825 staff and has a trailing 12-month revenue of around USD$1 billion.
Since the stock market crash in March caused by coronavirus, Neurocrine Biosciences's share price has had significant negative movement.
Its last market close was USD$92.96, which is 10.72% down on its pre-crash value of USD$104.12 and 28.86% up on the lowest point reached during the March crash when the shares fell as low as USD$72.14.
If you had bought USD$1,000 worth of Neurocrine Biosciences shares at the start of February 2020, those shares would have been worth USD$786.94 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$925.88.
|Latest market close||USD$92.96|
|52-week range||USD$72.14 - USD$136.2618|
|50-day moving average||USD$97.1075|
|200-day moving average||USD$111.6256|
|Wall St. target price||USD$126.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.963|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||4.45%|
|1 month (2020-10-30)||-5.79%|
|3 months (2020-08-28)||-18.68%|
|6 months (2020-05-29)||-25.49%|
|1 year (2019-11-29)||-20.28%|
|2 years (2018-11-29)||7.20%|
|3 years (2017-11-29)||35.91%|
|5 years (2015-11-27)||61.30%|
Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Neurocrine Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 92x. In other words, Neurocrine Biosciences shares trade at around 92x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Neurocrine Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.87. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Neurocrine Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Neurocrine Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$349.1 million.
The EBITDA is a measure of a Neurocrine Biosciences's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1 billion|
|Operating margin TTM||32.69%|
|Gross profit TTM||USD$580.6 million|
|Return on assets TTM||15.87%|
|Return on equity TTM||13.55%|
|Market capitalisation||USD$8.9 billion|
TTM: trailing 12 months
There are currently 5.1 million Neurocrine Biosciences shares held short by investors – that's known as Neurocrine Biosciences's "short interest". This figure is 1.8% up from 5.0 million last month.
There are a few different ways that this level of interest in shorting Neurocrine Biosciences shares can be evaluated.
Neurocrine Biosciences's "short interest ratio" (SIR) is the quantity of Neurocrine Biosciences shares currently shorted divided by the average quantity of Neurocrine Biosciences shares traded daily (recently around 993451.65048544). Neurocrine Biosciences's SIR currently stands at 5.15. In other words for every 100,000 Neurocrine Biosciences shares traded daily on the market, roughly 5150 shares are currently held short.
However Neurocrine Biosciences's short interest can also be evaluated against the total number of Neurocrine Biosciences shares, or, against the total number of tradable Neurocrine Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neurocrine Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Neurocrine Biosciences shares in existence, roughly 50 shares are currently held short) or 0.0523% of the tradable shares (for every 100,000 tradable Neurocrine Biosciences shares, roughly 52 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Neurocrine Biosciences.
Find out more about how you can short Neurocrine Biosciences stock.
We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $72.14 up to $136.2618. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 1.1443. This would suggest that Neurocrine Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL ? Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.